Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
8.14
-0.05 (-0.61%)
At close: Nov 20, 2024, 4:00 PM
8.23
+0.09 (1.11%)
Pre-market: Nov 21, 2024, 7:14 AM EST
Iovance Biotherapeutics Revenue
Iovance Biotherapeutics had revenue of $58.56M in the quarter ending September 30, 2024, with 12,385.07% growth. This brings the company's revenue in the last twelve months to $90.86M, up 12,751.20% year-over-year. In the year 2023, Iovance Biotherapeutics had annual revenue of $1.19M.
Revenue (ttm)
$90.86M
Revenue Growth
+12,751.20%
P/S Ratio
24.88
Revenue / Employee
$163,120
Employees
557
Market Cap
2.48B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
PACS Group | 3.56B |
QuidelOrtho | 2.82B |
Amneal Pharmaceuticals | 2.68B |
Privia Health Group | 1.72B |
Catalyst Pharmaceuticals | 460.48M |
Vericel | 226.84M |
SpringWorks Therapeutics | 135.49M |
Janux Therapeutics | 13.05M |
IOVA News
- 9 days ago - Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity - Seeking Alpha
- 13 days ago - Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 - GlobeNewsWire
- 20 days ago - Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024 - GlobeNewsWire
- 6 weeks ago - Iovance Biotherapeutics: Moving To The Next Phase - Seeking Alpha
- 2 months ago - Iovance Biotherapeutics to Present at Upcoming Conferences - GlobeNewsWire
- 3 months ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade) - Seeking Alpha